Relay Therapeutics, Inc.
Tremor tracks 2 of its cancer trials.
Company-wide warning signs
These add points to every one of this company's trials.
- 3 insiders sold shares within a monthSince Oct 28, 2026+9
Trials
- RLAYRelay Therapeutics, Inc.9Calm
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Signing up patientsPhase 3540 patientsMain results: Apr 30, 2028 - RLAYRelay Therapeutics, Inc.9Calm
A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors
Signing up patientsPhase 1/2180 patientsMain results: May 31, 2029
Key executives leaving
From the last 12 months of the company's SEC reports.
Insider trades (last 6 months)
“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.
26 sales (7 not pre-planned) · 0 purchases
- Rahmer PeterSee remarks · Oct 28, 2026Sold 753 sharesabout $14 thousand · not pre-planned
- Bergstrom Donald APresident, R&D · Oct 28, 2026Sold 2,252 sharesabout $42 thousand · not pre-planned
- Catinazzo ThomasChief Financial Officer · Oct 28, 2026Sold 1,469 sharesabout $27 thousand · not pre-planned
- Patel SanjivPresident and CEO · Oct 7, 2026Sold 48,199 sharesabout $872 thousand · pre-planned
- Catinazzo ThomasChief Financial Officer · Oct 6, 2026Sold 17,511 sharesabout $325 thousand · pre-planned
- Catinazzo ThomasChief Financial Officer · Oct 6, 2026
Recent SEC filings
Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.